Pay in 4 interest-free payments of $7.23 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Novo is not alone in investing in combination approaches: in AstraZenecas 2023 announcement of its acquisition of Eccogenes GLP-1 program, the manufacturer noted that they intend to combine the GLP-1 asset with other products in their portfolio (e.g., Farxiga, baxdrostat) in an effort to address obesity comorbidities (e.g., heart disease, kidney disease, metabolic syndrome)
GLP-1 drugs: Employers annual claims may rise in 2025
Future Developments in Weight Loss Drugs The future trajectory of weight loss drugs is not solely determined by their potency and market value estimated to be worth $90 billion
Its no longer a story about novelty or shock value
US$ 26.05
US$ 29.91
US$ 26.82
US$ 20.61
US$ 23.38
